NCT04994808View on ClinicalTrials.gov

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

January 16, 2026

Study Completion Date

July 16, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Clofarabine

Given IV

DRUG

Fludarabine

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo HCT

RADIATION

Total-Body Irradiation

Undergo TBI

DRUG

Treosulfan

Given IV

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Medexus Pharma, Inc.
All Listed Sponsors
collaborator

Medexus Pharma, Inc.

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER